<DOC>
	<DOCNO>NCT02553707</DOCNO>
	<brief_summary>This study ass short term efficacy ibandronate ( 6 mg intravenous [ IV ] ) participant breast cancer malignant bone disease , moderate severe pain . All participant receive IV infusion ibandronate Days 1 , 2 , 3 , pain response measure Days 1-7 . The anticipated time study treatment 3 day , target sample size 182 individual .</brief_summary>
	<brief_title>A Study Assess Short Term Efficacy Intravenous Ibandronate ( Bondronat ) Participants With Metastatic Bone Pain Due Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Female participant great equal ( &gt; = ) 18 year age Breast cancer bone metastases Pain score &gt; =4 Worst Pain scale Brief Pain Inventory ( BPI ) Stable analgesic regimen . Participants receive bisphosphonate within 3 week start trial Radiotherapy bone within 4 week enrolment Hypersensitivity ibandronate Central nervous system ( CNS ) meningeal metastasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>